ACRUX Ltd (ACR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACRUX Ltd (ACR) has a cash flow conversion efficiency ratio of -3.930x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.02 Million ≈ $-2.84 Million USD) by net assets (AU$1.02 Million ≈ $723.84K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of ACRUX Ltd for the company's overall valuation and market capitalisation.
ACRUX Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how ACRUX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ACRUX Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACRUX Ltd ranked by their cash flow conversion efficiency. Explore ACRUX Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telo Genomics Corp
V:TELO
|
11.261x |
|
Schroder Income Growth Fund
LSE:SCF
|
0.006x |
|
XMReality AB
ST:XMR
|
0.069x |
|
Impera Capital S.A.
WAR:IMP
|
-0.010x |
|
DGB Asia Bhd
KLSE:0152
|
0.007x |
|
LOBE SCIENCES LTD
F:6YX0
|
N/A |
|
Mlabs Systems Bhd
KLSE:0085
|
0.091x |
|
Xamble Group Ltd
AU:XGL
|
13.406x |
Annual Cash Flow Conversion Efficiency for ACRUX Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of ACRUX Ltd from 2002 to 2025. View ACRUX Ltd (ACR) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.02 Million ≈ $723.84K |
AU$-5.47 Million ≈ $-3.87 Million |
-5.348x | -307.16% |
| 2024-06-30 | AU$3.28 Million ≈ $2.32 Million |
AU$-4.30 Million ≈ $-3.04 Million |
-1.313x | -1724.77% |
| 2023-06-30 | AU$8.70 Million ≈ $6.15 Million |
AU$703.00K ≈ $497.42K |
0.081x | +108.33% |
| 2022-06-30 | AU$9.09 Million ≈ $6.43 Million |
AU$-8.82 Million ≈ $-6.24 Million |
-0.970x | -57.00% |
| 2021-06-30 | AU$18.47 Million ≈ $13.07 Million |
AU$-11.41 Million ≈ $-8.08 Million |
-0.618x | +6.95% |
| 2020-06-30 | AU$12.85 Million ≈ $9.09 Million |
AU$-8.53 Million ≈ $-6.04 Million |
-0.664x | -46.59% |
| 2019-06-30 | AU$21.94 Million ≈ $15.52 Million |
AU$-9.94 Million ≈ $-7.03 Million |
-0.453x | -157.07% |
| 2018-06-30 | AU$29.97 Million ≈ $21.21 Million |
AU$-5.28 Million ≈ $-3.74 Million |
-0.176x | -244.00% |
| 2017-06-30 | AU$43.92 Million ≈ $31.08 Million |
AU$5.38 Million ≈ $3.80 Million |
0.122x | -67.46% |
| 2016-06-30 | AU$43.89 Million ≈ $31.05 Million |
AU$16.51 Million ≈ $11.68 Million |
0.376x | +45.25% |
| 2015-06-30 | AU$40.62 Million ≈ $28.74 Million |
AU$10.52 Million ≈ $7.44 Million |
0.259x | -70.06% |
| 2014-06-30 | AU$42.06 Million ≈ $29.76 Million |
AU$36.37 Million ≈ $25.73 Million |
0.865x | +538.23% |
| 2013-06-30 | AU$46.75 Million ≈ $33.08 Million |
AU$6.33 Million ≈ $4.48 Million |
0.135x | +395.86% |
| 2012-06-30 | AU$53.10 Million ≈ $37.57 Million |
AU$-2.43 Million ≈ $-1.72 Million |
-0.046x | -103.22% |
| 2011-06-30 | AU$45.71 Million ≈ $32.34 Million |
AU$65.10 Million ≈ $46.07 Million |
1.424x | +138.17% |
| 2010-06-30 | AU$80.47 Million ≈ $56.94 Million |
AU$48.12 Million ≈ $34.05 Million |
0.598x | +422.97% |
| 2009-06-30 | AU$31.22 Million ≈ $22.09 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-0.185x | -160.08% |
| 2008-06-30 | AU$38.11 Million ≈ $26.96 Million |
AU$-2.71 Million ≈ $-1.92 Million |
-0.071x | +83.13% |
| 2007-06-30 | AU$18.25 Million ≈ $12.91 Million |
AU$-7.70 Million ≈ $-5.45 Million |
-0.422x | -5.57% |
| 2006-06-30 | AU$20.58 Million ≈ $14.56 Million |
AU$-8.23 Million ≈ $-5.82 Million |
-0.400x | -99.63% |
| 2005-06-30 | AU$29.48 Million ≈ $20.86 Million |
AU$-5.90 Million ≈ $-4.18 Million |
-0.200x | +57.55% |
| 2004-06-30 | AU$8.41 Million ≈ $5.95 Million |
AU$-3.97 Million ≈ $-2.81 Million |
-0.472x | -200.45% |
| 2002-06-30 | AU$17.49 Million ≈ $12.37 Million |
AU$-2.74 Million ≈ $-1.94 Million |
-0.157x | -- |
About ACRUX Ltd
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more